CpG oligodeoxynucleotide inhibits HBV replication in a hydrodynamic injection murine model

Area of Science:

• Immunology
• Hepatology
• Virology

Background:

• Chronic Hepatitis B virus (HBV) infection is a major cause of liver disease and cancer.
• HBV infection leads to immune tolerance, hindering effective therapy.
• CpG oligodeoxynucleotides (ODN) are potent immune stimulants with therapeutic potential for viral infections.

Purpose of the Study:

• To evaluate the anti-HBV activity of CpG-1826.
• To assess the impact of CpG-1826 on HBV replication and host immune response in a murine model.

Main Methods:

• HBV carrier mice were established via hydrodynamic injection.
• CpG-1826 was administered intraperitoneally, and HBV markers (HBsAg, HBeAg, HBV DNA) were measured.
• Immune mediators (IFN-α, IFN-γ, HBsAb, HBcAb) and liver enzymes (ALT) were quantified.
• Drug toxicity was assessed through body weight and liver histopathology.

Main Results:

• CpG-1826 significantly reduced serum HBsAg, HBeAg, hepatic HBcAg, and HBV DNA.
• Increased levels of IFN-α, IFN-γ, and HBsAb were observed, while HBcAb decreased.
• No significant changes in ALT activity or obvious toxicity were detected.

Conclusions:

• CpG ODN, like CpG-1826, represents a promising therapeutic strategy for HBV infection by stimulating the host immune system.
• Further research is warranted to explore the full potential of CpG ODN in HBV treatment.